Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | STAT3 | P40763 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.52 |
| ▸ | MAPT | P10636 | 8/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1420805 | 0.83 | ANPEP (0.67) | ANPEPLMNASTAT3ALDH1A1MAPT | |
| SCHEMBL10335141 | 0.82 | KDM4E (0.54) | ANPEPLMNASTAT3ALDH1A1MAPT | |
| SCHEMBL1478386 | 0.81 | ANPEP (0.65) | ANPEPLMNASTAT3ALDH1A1MAPT | |
| SCHEMBL4751264 | 0.81 | ANPEP (0.65) | ANPEPLMNASTAT3ALDH1A1MAPT | |
| SCHEMBL23662790 | 0.81 | ANPEP (0.59) | ANPEPLMNASTAT3ALDH1A1MAPT | |
| SCHEMBL9362310 | 0.81 | MAPT (0.54) | ANPEPLMNAALDH1A1MAPTPKM | |
| SCHEMBL5278158 | 0.81 | ANPEP (0.64) | ANPEPLMNASTAT3ALDH1A1MAPT | |
| SCHEMBL9376852 | 0.79 | ANPEP (0.61) | ANPEPLMNASTAT3ALDH1A1MAPT | |
| SCHEMBL1269611 | 0.78 | MEN1 (0.59) | ANPEPLMNAALDH1A1MAPTPOLB | |
| SCHEMBL7407 | 0.78 | FFAR1 (0.68) | LMNAALDH1A1MAPTPOLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | US | disclosed |
| WO-2021046549-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| US-8314155-B2 | Bicyclic aromatic sulfinyl derivatives | CEPHALON, INC (US) | 2012-11-20 | — | — | US | disclosed |
| US-7893077-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893077-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893077-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100120700-A1 | METHODS AND COMPOSITIONS FOR TREATING CERVICAL CANCER | ARBOR VITA CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| EP-1786782-B1 | BISARYL-SULFONAMIDES | AMGEN INC (US) | 2010-03-31 | — | — | EP | disclosed |
| EP-1786782-B1 | BISARYL-SULFONAMIDES | AMGEN INC (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090221584-A1 | Bisaryl-sulfonamides | AMGEN INC. | 2009-09-03 | — | — | US | disclosed |
| EP-1786782-A2 | BISARYL-SULFONAMIDES | Amgen Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20070099199-A1 | Methods and compositions for treating cervical cancer | ARBOR VITA CORPORATION | 2007-05-03 | — | — | US | disclosed |
| EP-1599214-A4 | METHODS AND COMPOSITIONS FOR TREATING CERVICAL CANCER | ARBOR VITA CORP (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20060084802-A1 | Bisaryl-sulfonamides | AMGEN INC. | 2006-04-20 | — | — | US | disclosed |
| WO-2006020830-A2 | BISARYL-SULFONAMIDES | AMGEN INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| EP-1599214-A2 | METHODS AND COMPOSITIONS FOR TREATING CERVICAL CANCER | Arbor Vita Corporation (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20040229298-A1 | Methods and compositions for treating cervical cancer | ARBOR VITA CORPORATION | 2004-11-18 | — | — | US | disclosed |
| WO-2004076646-A2 | METHODS AND COMPOSITIONS FOR TREATING CERVICAL CANCER | ARBOR VITA CORPORATION (US) | 2004-09-10 | — | — | WO | disclosed |
| EP-0607217-A1 | PYRIDINOL DERIVATIVES AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1994-07-27 | — | — | EP | disclosed |
| WO-1993007137-A1 | PYRIDINOL DERIVATIVES AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221584-A1 | Bisaryl-sulfonamides | PPARD, PPARA, PPARG | ANPEP 2612/4885LMNA 2576/4885STAT3 766/4885 |
| US-20210228727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | ANPEP 14/4885LMNA 3451/4885STAT3 4477/4885 |
| US-20100120700-A1 | METHODS AND COMPOSITIONS FOR TREATING CERVICAL CANCER | MAGI3, PDLIM5, PYM1 | ANPEP 874/4885LMNA 2407/4885STAT3 4039/4885 |
| US-20060084802-A1 | Bisaryl-sulfonamides | PPARD, PPARA, PPARG | ANPEP 2612/4885LMNA 2576/4885STAT3 766/4885 |
| US-20040229298-A1 | Methods and compositions for treating cervical cancer | MAGI3, PDLIM5, PYM1 | ANPEP 874/4885LMNA 2407/4885STAT3 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.